Diabetes Prevention Program Pilot Study
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 4/21/2016 |
| Start Date: | December 2008 |
| End Date: | October 2009 |
Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study
This pilot study is intended to demonstrate that we can actually deliver the Diabetes
Prevention Program intervention well and to show that it is likely effective. We will use
results from this pilot study to support our application to The National Institute of
Health. NIH is asking for health care centers to show ways to provide this treatment at a
reasonable cost. We propose to demonstrate successful and sustainable use DPP's lifestyle
intervention in a primary care health care setting (University of Rochester Primary Care).
Prevention Program intervention well and to show that it is likely effective. We will use
results from this pilot study to support our application to The National Institute of
Health. NIH is asking for health care centers to show ways to provide this treatment at a
reasonable cost. We propose to demonstrate successful and sustainable use DPP's lifestyle
intervention in a primary care health care setting (University of Rochester Primary Care).
Inclusion Criteria:
- Age >18 years
- BMI >24 kg/m2 (>22 kg/m2 among Asian Americans)
- IGT (2-h plasma glucose 140~199 mg/dl based on 75-g OGTT if available). The OGTT will
not be required for inclusion, but the CMA practitioners may wish to recommend the
OGTT for their patients.
- Elevated FPG (95~125 mg/dl*).
- HDL-triglyceride ration > 3.5.
Exclusion Criteria:
- Diabetes at baseline
- FPG >126 mg/dl*
- 2-h plasma glucose >200 mg/dl based on 75-g OGTT, if available. OGTT will not be
required (see above note).
- Diabetes diagnosed by a physician and confirmed by other clinical data, other than
during pregnancy.
- Ever used antidiabetic medication, other than during pregnancy
- Medical conditions likely to limit life span and/or increase risk of intervention
- Cardiovascular disease
- Hospitalization for treatment of heart disease in past 6 months New York Heart
Association Functional Class> 2
- Left bundle branch block or third degree AV block Aortic stenosis
- Systolic blood pressure> 180 mmHg or diastolic blood pressure> 105 mmHg
- Cancer requiring treatment in the past 5 years, unless the prognosis is considered
good
- Renal disease (creatinine GFR < or = 30 ml/hr or > 2.0 mg/dl if GFR not available).
- Anemia (hematocrit <36% in men or <33% in women)
- Hepatitis (based on history or serum transaminase elevation)
- Other gastrointestinal disease (pancreatitis, acute inflammatory bowel disease)
- Recent or significant abdominal surgery
- Pulmonary disease with dependence on oxygen or daily use of bronchodilators
- Chronic infection (e.g., HIV, active tuberculosis)
- Conditions or behaviors likely to affect conduct of the trial
- Unable to communicate with clinic staff (e.g., read and speak English).
- Unwilling to accept treatment assignment by randomization
- Participation in another intervention research project that might interfere with DPP
- Weight loss of > 10% in past 6 months for any reason except postpartum weight loss
- Unable to walk 0.25 miles in 10 min
- Currently pregnant or within 3 months postpartum
- Currently nursing or within 6 weeks of having completed nursing
- Pregnancy anticipated during the course of the trial
- Unwilling to undergo pregnancy testing or report possible pregnancy promptly
- Unwilling to take adequate contraceptive measures, if potentially fertile
- Major psychiatric disorder, including severe active major depression, severe anxiety,
schizophrenia, manic depression, bi-polar disorder
- Excessive alcohol intake, either acute or chronic
- Medications and medical conditions likely to confound the assessment for diabetes
including:
- Niacin, in doses indicated for lowering serum triglycerides
- Glucocorticoids, systemic
- Other prescription weight-loss medications
- Active Thyroid disease, suboptimally treated as indicated by abnormal serum
thyroid-stimulating hormone
- Other endocrine disorders (e.g., Cushing's syndrome, acromegaly)
- Fasting plasma triglyceride >600 mg/dl, despite treatment
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials